Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms
Status:
Not yet recruiting
Trial end date:
2024-12-28
Target enrollment:
Participant gender:
Summary
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and
XALKORI - Crizotinib therapeutic-effects in patients with non-small cell lung cancer, based
on Oxford precisely sequencing drug targets' genes.
Explore the relationship between drug target CYP4503A gene single nucleotide polymorphisms
and XALKORI - Crizotinib side-effects in patients with non-small cell lung cancer, based on
Oxford precisely sequencing drug targets' genes.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair